Ascentage Pharma Announces Purchase of 110,000 Shares by Trustee for 2022 RSU Scheme

On June 11, 2026, Ascentage Pharma Group International announced that the Trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing ordinary shares on-market. The shares were acquired at an average price of approximately HK$33.37 per share, totaling a consideration of HK$3,671,094 (excluding transaction costs). This purchase represents approximately 0.0294% of the company's total issued shares as of the announcement date. The transaction was conducted to satisfy the vesting of RSUs previously granted under the 2022 RSU Scheme. Following this acquisition, the total number of shares held by the Trustee for the purpose of the scheme has reached 2,615,000 shares. These shares are held in trust, and the Trustee is prohibited from exercising voting rights associated with them. This filing follows a series of previous announcements regarding the adoption and ongoing administration of the company's equity incentive plans.